Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer

Management to host conference call today at 8:30 a.m. Eastern SAN DIEGO, Sept. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Toca 5 P... Biopharmaceuticals, Oncology Tocagen, glioma, brain cancer, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news